JR is the CEO & Co-Founder of MindMed (NASDAQ: MNMD), the first ever publicly listed psychedelic medicine company. MindMed is a clinical-stage psychedelic medicine biotech company addressing mental illness and addiction. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. Before starting MindMed, JR worked in market expansion and operations at Uber and led a previous fintech startup through Y Combinator in Silicon Valley.